FLT3-ITD急性髓系白血病患者异基因造血干细胞移植后索拉非尼维持治疗:开放标签、多中心、随机、3期试验的长期随访
该3期试验在中国7家医院纳入202例接受异基因造血干细胞移植的FLT3-ITD急性髓系白血病患者,随机分为索拉非尼维持治疗组(n=100)与不维持治疗对照组(n=102)。中位随访60.4个月显示,索拉非尼组总生存、无白血病生存、无GVHD无复发生存均优于对照组,复发累积发生率更低,非复发死亡率未增加。
要点
- 索拉非尼维持组5年总生存72.0% vs 对照组55.9%(HR 0.55,95%CI 0.34-0.88;p=0.011)。
- 索拉非尼维持组5年复发累积发生率15.0% vs 对照组36.3%(HR 0.33,95%CI 0.18-0.60;p=0.0003)。
- 两组5年慢性GVHD累积发生率无显著差异(54.0% vs 51.0%;HR 0.82,95%CI 0.56-1.19;p=0.73)。
核心结论
- 延长随访显示,移植后索拉非尼维持治疗与长期生存改善和复发率降低相关,进一步支持该策略作为接受异基因造血干细胞移植的FLT3-ITD急性髓系白血病患者的标准治疗。
研究设计与样本
- 开放标签、多中心、随机、3期试验,在中国7家医院纳入202例接受异基因造血干细胞移植的FLT3-ITD急性髓系白血病患者。
- 患者年龄18-60岁,ECOG体能状态0-2,移植前后达复合完全缓解,移植后60天内造血恢复。
- 移植后30-60天按1:1随机分配至索拉非尼维持治疗组(400 mg口服,每日两次;n=100)或不维持治疗对照组(n=102)。
- 随机化采用置换区组(区组大小4)通过交互式网络系统进行,研究者和参与者未设盲。
- 本次为事后分析,报告意向治疗人群的5年终点;试验注册号NCT02474290,已完成。
主要发现
- 中位随访60.4个月(IQR 16.7-73.3)。
- 索拉非尼组 vs 对照组5年总生存:72.0%(95%CI 62.1-79.7)vs 55.9%(95%CI 45.7-64.9);HR 0.55(95%CI 0.34-0.88);p=0.011。
- 索拉非尼组 vs 对照组5年无白血病生存:70.0%(95%CI 60.0-78.0)vs 49.0%(95%CI 39.0-58.3);HR 0.47(95%CI 0.30-0.73);p=0.0007。
- 索拉非尼组 vs 对照组5年无GVHD无复发生存:58.0%(95%CI 47.7-67.0)vs 39.2%(95%CI 29.8-48.5);HR 0.56(95%CI 0.38-0.83);p=0.0030。
- 索拉非尼组 vs 对照组5年复发累积发生率:15.0%(95%CI 8.8-22.7)vs 36.3%(95%CI 27.0-45.6);HR 0.33(95%CI 0.18-0.60);p=0.0003。
关键数值与推荐
- 索拉非尼维持治疗剂量为400 mg口服,每日两次。
- 索拉非尼维持治疗于移植后30-60天开始。
- 两组5年慢性GVHD累积发生率:索拉非尼组54.0%(95%CI 43.7-63.2)vs 对照组51.0%(95%CI 40.8-60.3);HR 0.82(95%CI 0.56-1.19);p=0.73,无显著差异。
- 两组间迟发效应未发现实质性差异。
- 无治疗相关死亡。
临床怎么用
- 作者认为,移植后索拉非尼维持治疗与长期生存改善和复发率降低相关,进一步支持该策略作为接受异基因造血干细胞移植的FLT3-ITD急性髓系白血病患者的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our open-label, multicentre, randomised, phase 3 trial showed that sorafenib maintenance after haematopoietic stem-cell transplantation (HSCT) improved overall survival and reduced relapse for patients with FLT3 internal tandem duplication (FLT3-ITD) acute myeloid leukaemia undergoing allogeneic HSCT. Here, we present a post-hoc analysis on the 5-year follow-up data of this trial. METHODS: This phase 3 trial, done in seven hospitals in China, included patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic HSCT, who were aged 18-60 years, had an Eastern Cooperative Oncology Group performance status of 0-2, had composite complete remission before and after transplantation, and had haematopoietic recovery within 60 days after transplantation. Patients were randomly assigned (1:1) to receive sorafenib maintenance (400 mg orally twice daily) or non-maintenance (control) at 30-60 days after transplantation. Randomisation was done with permuted blocks (block size four) via an interactive web-based system. Investigators and participants were not masked to group assignment. The primary endpoint was the 1-year cumulative incidence of relapse, which was reported previously. For this updated analysis, the 5-year endpoints were overall survival; cumulative incidence of relapse; non-relapse mortality; leukaemia-free survival; graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS); cumulative incidence of chronic GVHD; and late effects in the intention-to-treat population. The trial is registered with ClinicalTrials.gov, NCT02474290, and is complete. FINDINGS: Between June 20, 2015, and July 21, 2018, 202 patients were randomly assigned to sorafenib maintenance (n=100) or non-maintenance (n=102). Median follow-up was 60·4 months (IQR 16·7-73·3). Extended follow-up showed improved overall survival (72·0% [95% CI 62·1-79·7] vs 55·9% [45·7-64·9]; hazard ratio [HR] 0·55, 95% CI 0·34-0·88; p=0·011), leukaemia-free survival (70·0% [60·0-78·0] vs 49·0% [39·0-58·3]; 0·47, 0·30-0·73; p=0·0007), and GRFS (58·0% [47·7-67·0] vs 39·2% [29·8-48·5]; 0·56, 0·38-0·83; p=0·0030), lower cumulative incidence of relapse (15·0% [8·8-22·7] vs 36·3% [27·0-45·6]; 0·33, 0·18-0·60; p=0·0003), and no increase in non-relapse mortality (15·0% [8·8-22·7] vs 14·7% [8·6-22·3]; 0·79, 0·39-1·62; p=0·98) for patients in the sorafenib group compared with those in the control group. The 5-year cumulative incidence of chronic GVHD (54·0% [43·7-63·2] vs 51·0% [40·8-60·3]; 0·82, 0·56-1·19; p=0·73) did not differ significantly between the two groups and we did not find substantial differences in late effects between the two groups. There were no treatment-related deaths. INTERPRETATION: With extended follow-up, sorafenib maintenance after transplantation is associated with improved long-term survival and reduced relapse rates compared with non-maintenance, further supporting this strategy as a standard of care for patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic HSCT. FUNDING: None. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Xuan L, Wang Y, Yang K, et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2023. PMID: 37414062. doi:10.1016/S2352-3026(23)00117-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。